BioSpace News Archive

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on June 2, 2021, at 4:00 p.m. EDT.

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company developing onvansertib to treat cancers with the greatest medical needs for new treatment options, including KRAS-mutated colorectal cancer, pancreatic cancer and castrate-resistant prostate cancer, today announced that Dr. Mark Erlander,

Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced today that the U.S. Food and Drug Administration (US FDA) has provided details of the additional information it is requesting regarding its Chimeric Antigen Receptor-T cell therapy

Shuttle Pharmaceuticals Holdings, Inc., (Shuttle Pharma) a clinical stage company developing drugs to improve the treatment of cancer patients undergoing radiation therapy is pleased to announce the addition of Chris Senanayake , PhD as a member of its Board of Directors.

Carestream Selects HPE GreenLake Cloud Services to Power Transformative Artificial Intelligence-as-a-service (AIaas)

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO; Andrew Last, Executive Vice President and COO; and Ilan Daskal, Executive Vice President and CFO, will participate in a Fireside Chat at Jefferies Virtual Healthcare Conference on Wednesday, June 2, at noon (Pacific Time).

Tempus, a leader in artificial intelligence and precision medicine, today announced the launch of its cloud-based data and analytics platform, Lens.

Horizon Therapeutics plc Named One of the 2021 Best Workplaces in Chicago™ by Great Place to Work ®

Advanced Human Imaging Limited (ASX: AHI) (“AHI” or the “Company”) is pleased to announce that it has signed a binding term sheet with U.S. based Jana Care Inc. (Jana Care), a developer and manufacturer of the Aina Blood Monitoring Device (the Aina Device).

PRIMROSE 1 76-week results confirmPRIMROSE 2 data showing sustained post-treatment effects and evidence of bone mineral density (BMD) recovery following 52 weeks of treatment